Neuland Laboratories Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/q2qlm2xe4z4x61xklsuxih8i.pdf

Key Takeaways


The Lumpiness Reality

Saharsh Davuluri: "The same lumpiness that resulted in a record-breaking Q4, if you recall, also made the previous quarter, which is Q3FY26 a relatively muted quarter. And it's worth stating the obvious. The lumpiness does not recognize financial year boundaries, right? It doesn't recognize or it doesn't care about March 31."

FY26 Performance Drivers

Saharsh Davuluri: "This exceptional operating margin reflects the record high revenue this quarter. And it is also partly because of a function of the uneven nature of our revenue flows and should not be seen as an indicator of our future performance."

Peptide Strategy & Investment

Saharsh Davuluri: "I think the short answer is that it has the potential to create another Neuland for sure. It may take a few years, it may take more than a few years."

Capital Allocation & Operating Model

Saharsh Davuluri: "I think that's the game that needs to be played and that requires a different mindset of capital allocation, which is what was being referred to in the opening remarks."

Leadership & Organizational Updates


Pipeline & Demand Environment


Guidance & Commitments

CommitmentSpecificsTimeline
Working capital normalizationDays to normalize from 137 toward historical levelsFY27
Peptide facility completionFacility ready; validations and qualifications to followJuly FY27
One commercializationOne product entering commercial stage, possibly 1–2 more laterFY27
Growth visibilityExisting pipeline of commercial and near-commercial molecules drives growthNext 2–3 years
ROCE moderationExpected as longer capital deployment cycles beginNo specific timeline
Volatility persistenceNew molecules will continue to bring lumpiness; "25% times 4" not expected soonOngoing

Key Metrics

MetricQ4 FY26
Total income₹788.7 cr, up 134.9% YoY from ₹335.8 cr
CMS revenue shareOver two-thirds of total revenue in Q4
Gross margin62.1%, up from 56.3% in Q4 FY25, driven by business mix
EBITDA₹319.4 cr, margin of 40.5%, reflecting record high revenue and lumpy flows
Profit after tax₹212.5 cr, versus ₹27.7 cr in Q4 FY25
EPS₹165.6 per share
FY26 revenue₹2,053.1 cr, growth of 37.1% over FY25
FY26 EBITDA margin29.4%, versus 22.9% in FY25
FY26 PAT₹363.1 cr, EPS ₹283.01 per share
Free cash flow (FY26)Negative ₹49.4 cr, driven by higher working capital and capex
Capex cash outflow (FY26)₹397.1 cr
Working capital days137 days, versus 107 days in Q4 FY25, driven by higher inventories and receivables
Net debtNegative ₹157 cr, with cash balances of ₹353 cr and long-term borrowings of ₹197 cr
Capacity utilization85–90% across three units, last unit at 65%
Peptide CDMO market opportunity$5–6 bn, with a healthy CAGR